You are here

  • Home
  • Impact
  • Publications
  • Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Aldridge, A., Kroutil, L., Cowell, A., Reeves, D., & Van Brunt, D. (2011). Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder. PharmacoEconomics, 29(7)(1170-7690), 621 - 635.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Meet the Experts

View All Experts
Alexander Cowell

Alexander Cowell
arnie aldridge

Arnie Aldridge
Larry Kroutil

Larry Kroutil

Recent Publications

Article

The evolution of minimally invasive tissue sampling in postmortem examination
Article

Accountability for SRHR in the context of the COVID-19 pandemic
Article

Validation of simple dichotomous self-report on prenatal alcohol and other drug use in women attending midwife obstetric units in the Cape Metropole, South Africa
Article

Nicotinic acetylcholine receptor accessory subunits determine the activity profile of epibatidine derivatives

RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept